KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Cash (2023 - 2025)

Biocryst Pharmaceuticals' Change in Cash history spans 9 years, with the latest figure at -$9.6 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 231.7% year-over-year to -$9.6 million; the TTM value through Dec 2025 reached -$15.0 million, down 144.71%, while the annual FY2025 figure was -$15.0 million, 144.71% down from the prior year.
  • Change in Cash reached -$9.6 million in Q4 2025 per BCRX's latest filing, down from -$4.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $18.9 million in Q3 2024 to a low of -$149.6 million in Q1 2023.
  • Average Change in Cash over 3 years is -$17.9 million, with a median of -$5.0 million recorded in 2024.
  • Peak YoY movement for Change in Cash: surged 301.26% in 2024, then plummeted 231.7% in 2025.
  • A 3-year view of Change in Cash shows it stood at -$40.0 million in 2023, then soared by 118.13% to $7.3 million in 2024, then tumbled by 231.7% to -$9.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Change in Cash are -$9.6 million (Q4 2025), -$4.1 million (Q3 2025), and -$1.9 million (Q2 2025).